Earnings
Harmony's Next CEO Says Its $1 Billion-Plus Cash Won't Go On One Deal
Peter Anastasiou, who becomes CEO January 1, 2027, plans multiple deals and a search beyond rare neurological disease.
Harmony Biosciences (HRMY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Peter Anastasiou, who becomes CEO January 1, 2027, plans multiple deals and a search beyond rare neurological disease.
Earnings
Cost of product sold rose from 24.9% a year earlier, and $35.0 million in milestone payments come due in the fourth quarter.
SEC Filings
The narcolepsy drugmaker held its 2026 WAKIX guidance at $1.0 billion to $1.04 billion and posted early safety data for BP-205.
SEC Filings
An amended filing sets Peter Anastasiou's pay as CEO and a $500-an-hour consulting deal for retiring chief Jeffrey Dayno.
SEC Filings
Dayno retires December 31 after a nine-year tenure, and the company kept its $1.0 billion to $1.04 billion 2026 WAKIX revenue guidance.